Targeting bromodomains: epigenetic readers of lysine acetylation.

Lysine acetylation is a key mechanism that regulates chromatin structure; aberrant acetylation levels have been linked to the development of several diseases. Acetyl-lysine modifications create docking sites for bromodomains, which are small interaction modules found on diverse proteins, some of whi...

Full description

Bibliographic Details
Main Authors: Filippakopoulos, P, Knapp, S
Format: Journal article
Language:English
Published: 2014
_version_ 1797103566531330048
author Filippakopoulos, P
Knapp, S
author_facet Filippakopoulos, P
Knapp, S
author_sort Filippakopoulos, P
collection OXFORD
description Lysine acetylation is a key mechanism that regulates chromatin structure; aberrant acetylation levels have been linked to the development of several diseases. Acetyl-lysine modifications create docking sites for bromodomains, which are small interaction modules found on diverse proteins, some of which have a key role in the acetylation-dependent assembly of transcriptional regulator complexes. These complexes can then initiate transcriptional programmes that result in phenotypic changes. The recent discovery of potent and highly specific inhibitors for the BET (bromodomain and extra-terminal) family of bromodomains has stimulated intensive research activity in diverse therapeutic areas, particularly in oncology, where BET proteins regulate the expression of key oncogenes and anti-apoptotic proteins. In addition, targeting BET bromodomains could hold potential for the treatment of inflammation and viral infection. Here, we highlight recent progress in the development of bromodomain inhibitors, and their potential applications in drug discovery.
first_indexed 2024-03-07T06:21:55Z
format Journal article
id oxford-uuid:f2fd6151-c82b-495e-85af-5479210b1670
institution University of Oxford
language English
last_indexed 2024-03-07T06:21:55Z
publishDate 2014
record_format dspace
spelling oxford-uuid:f2fd6151-c82b-495e-85af-5479210b16702022-03-27T12:08:25ZTargeting bromodomains: epigenetic readers of lysine acetylation.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f2fd6151-c82b-495e-85af-5479210b1670EnglishSymplectic Elements at Oxford2014Filippakopoulos, PKnapp, SLysine acetylation is a key mechanism that regulates chromatin structure; aberrant acetylation levels have been linked to the development of several diseases. Acetyl-lysine modifications create docking sites for bromodomains, which are small interaction modules found on diverse proteins, some of which have a key role in the acetylation-dependent assembly of transcriptional regulator complexes. These complexes can then initiate transcriptional programmes that result in phenotypic changes. The recent discovery of potent and highly specific inhibitors for the BET (bromodomain and extra-terminal) family of bromodomains has stimulated intensive research activity in diverse therapeutic areas, particularly in oncology, where BET proteins regulate the expression of key oncogenes and anti-apoptotic proteins. In addition, targeting BET bromodomains could hold potential for the treatment of inflammation and viral infection. Here, we highlight recent progress in the development of bromodomain inhibitors, and their potential applications in drug discovery.
spellingShingle Filippakopoulos, P
Knapp, S
Targeting bromodomains: epigenetic readers of lysine acetylation.
title Targeting bromodomains: epigenetic readers of lysine acetylation.
title_full Targeting bromodomains: epigenetic readers of lysine acetylation.
title_fullStr Targeting bromodomains: epigenetic readers of lysine acetylation.
title_full_unstemmed Targeting bromodomains: epigenetic readers of lysine acetylation.
title_short Targeting bromodomains: epigenetic readers of lysine acetylation.
title_sort targeting bromodomains epigenetic readers of lysine acetylation
work_keys_str_mv AT filippakopoulosp targetingbromodomainsepigeneticreadersoflysineacetylation
AT knapps targetingbromodomainsepigeneticreadersoflysineacetylation